Delving into the Latest Updates on Interferon alpha kinoid (Neovacs) with Synapse

The safety and immunogenicity of the IFNα-Kinoid (IFN-K) have been evaluated in a phase I clinical study conducted in subjects with Systemic Lupus Erythematosus (SLE). Preliminary results showed acceptable safety profile and patients developped antibodies response.
The principal aim of the present study is to confirm the neutralization of the interferon gene signature and the clinical efficacy of IFN-K in subjects with SLE. In addition, the immune responses and the safety elicited by IFN-K will also be evaluated.

Start Date23 Sep 2015

Sponsor / Collaborator

Neovacs SA

100 Clinical Results associated with Interferon alpha kinoid (Neovacs)

Login to view more data

100 Translational Medicine associated with Interferon alpha kinoid (Neovacs)

Login to view more data

100 Patents (Medical) associated with Interferon alpha kinoid (Neovacs)

Login to view more data

8

Literatures (Medical) associated with Interferon alpha kinoid (Neovacs)

01 Aug 2024·Marine Pollution Bulletin

Preliminary assessment of microplastic in rhizosphere and non-rhizosphere region of mangrove at four locations along Karachi coast, Pakistan

Article

Author: Alvi, Sofia Khalique ; Riaz, Shagufta ; Sahar, Rafia ; Rasool, Sarwat Ghulam ; Shafique, Seema ; Qader, Irfana ; Siddiqui, Pirzada J A ; Burhan, Zaib-Un-Nisa

Mangrove ecosystem faces significant threats from the various pollutants including microplastic (MPs). The aim of this study was to assess variations in MP distribution in mangrove sediments of rhizosphere (R) and non-rhizosphere (NR) regions. A total of 14,960 MP particles were identified from Sandspit backwater (SS-1 & SS-2) and Creek areas (PQ & KC). Notably, the NR showed higher MP counts (7848) compared to the R region (7112). Analysis revealed variations in MP types, with beads being predominant in both R and NR, followed by film, fiber, and fragments. KC exhibited highest MP contamination, followed by PQ, SS-2, and SS-1. Fourier-transform infrared (FTIR) analysis confirmed the presence of polyethylene terephthalate and polyethylene in sediments samples. This first detailed report on MP in mangrove sediments and other limited studies from Pakistan establishes the widespread distribution of MPs in the coastal area and provide a baseline for further elaboration in future.

01 Oct 2016·RheumatologyQ2 · MEDICINE

Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study

Q2 · MEDICINE

Article

Author: Frédéric A. Houssiau ; Thérèse Croughs ; Julie Ducreux ; Pierre Vandepapelière ; Géraldine Grouard-Vogel ; François Spertini ; Bernard R. Lauwerys ; Camille Roucairol ; Estibaliz Lazaro ; Christian Jorgensen ; Marion Laborie ; Fabien Colaone

OBJECTIVEIFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b coupled to a carrier protein. In a phase I/II placebo-controlled trial, we observed that IFN-K significantly decreases the IFN gene signature in whole blood RNA samples from SLE patients. Here, we analysed extended follow-up data from IFN-K-treated patients, in order to evaluate persistence of neutralizing anti-IFNα Abs antibodies (Abs), and gene expression profiling.METHODSSerum and whole blood RNA samples were obtained in IFN-K-treated patients included in the follow-up study, in order to determine binding and neutralizing anti-IFNα Ab titres, and perform high-throughput transcriptomic studies.RESULTSNeutralization studies of 13 IFNα subtypes demonstrated the polyclonal nature of the Ab response induced by IFN-K. Follow-up analyses in six patients confirmed a significant correlation between neutralizing anti-IFNα Ab titres and decrease in IFN scores compared to baseline. These analyses also revealed an inhibitory effect of IFNα blockade on the expression of B cell associated transcripts.CONCLUSIONSIFN-K induces a polyclonal anti-IFNα response that decreases IFN- and B cell-associated transcripts.TRIAL REGISTRATIONClinicalTrials.gov, clinicaltrials.gov, NCT01058343.

01 Jul 2014·Journal of Animal ScienceQ2 · AGRICULTURAL & FORESTRY SCIENCE

Use of a stair-step compensatory gain nutritional regimen to program the onset of puberty in beef heifers1

Q2 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Keisler, D. H. ; Williams, G. L. ; Park, C. S. ; Amstalden, M. ; Tedeschi, L. O. ; Thorson, J. F. ; Prezotto, L. D. ; Alves, B. R. C. ; Cardoso, R. C.

It was hypothesized that metabolic programming of processes underlying puberty can be shifted temporally through the use of a stair-step compensatory growth model such that puberty is optimally timed to occur at 11 to 12 mo of age. Forty crossbred beef heifers were weaned at approximately 3.5 mo of age and, after a 2-wk acclimation period, were assigned randomly to 1 of 4 nutritional groups: 1) low control (LC), restricted feed intake of a forage-based diet to promote BW gain of 0.5 kg/d until 14 mo of age, 2) high control (HC), controlled feed intake of a high-concentrate diet to promote BW gain of 1 kg/d until 14 mo of age, 3) stair-step 1 (SS-1), ad libitum feed intake of a high-concentrate diet until 6.5 mo of age followed by restricted access to a high-forage diet to promote BW gain of 0.35 kg/d until 9 mo of age, ad libitum feed intake of a high-concentrate diet until 11.5 mo of age, and restricted intake of a high-forage diet to promote BW gain of 0.35 kg/d until 14 mo of age, and 4) stair-step 2 (SS-2), reverse sequence of SS-1, beginning with restricted access to a high-forage diet. Body weight (every 2 wk) and circulating concentrations of leptin (monthly) were determined throughout the experiment. Concentrations of progesterone in blood samples collected twice weekly beginning at 8 mo of age were used to determine pubertal status. Body weight gain followed a pattern similar to that proposed in our experimental design. Circulating concentrations of leptin increased following distinct elevations in BW but decreased abruptly after feed intake restriction. Survival analysis indicated that the percentage of pubertal heifers in the LC group was lower (P < 0.05) than all other groups throughout the experiment. Although heifers in SS-1 were nutritionally restricted between 6.5 and 9 mo of age, the proportion pubertal by 12 mo of age did not differ (P = 0.36) from that of the HC group, with 80% and 70% pubertal in SS-1 and HC, respectively. In contrast, the proportion of heifers pubertal by 12 mo of age in the SS-2 group (40%) was lower (P < 0.05) than both HC and SS-1. However, by 14 mo of age, 90% of heifers in the SS-2 group had also attained puberty compared to only 40% of the LC group. In summary, these data provide evidence that changes in the nutritional and metabolic status during the early juvenile period can program the onset of puberty that occurs months later, allowing optimal timing of sexual maturation in replacement beef heifers.

100 Deals associated with Interferon alpha kinoid (Neovacs)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatomyositis	Discovery	CH	Neovacs SA	03 May 2017
Dermatomyositis	Discovery	DE	Neovacs SA	03 May 2017
Dermatomyositis	Discovery	FR	Neovacs SA	03 May 2017
Dermatomyositis	Discovery	IT	Neovacs SA	03 May 2017
Systemic Lupus Erythematosus	Discovery	GE	Neovacs SA	22 Aug 2015
Systemic Lupus Erythematosus	Discovery	GE	Neovacs SA	22 Aug 2015
Diabetes Mellitus, Type 1	Discovery	FR	Department Immunology of Diabetes at Hospital Cochin	-
Diabetes Mellitus, Type 1	Discovery	FR	Neovacs SA	-
HIV Infections	Discovery	FR	Sanofi Pasteur	-
Sjogren's Syndrome	Discovery	FR	Neovacs SA	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02665364 (CTgov)	Phase 2	Systemic Lupus Erythematosus	185	Placebo+ISA 51 VG	clvdfhrbnr(ksfszovwag) = fgnengzgsg yfizgvovmk (udnvcpmawt, hterxxpyap - zsgtiyqbtr) View more	-	26 Mar 2020
NCT02665364 (Pubmed \| Arthritis Rheumatol) Manual	Phase 2	Systemic Lupus Erythematosus	185	IFN-α kinoid	(xnafmfdnfd) = fzevqhnsrw ccwjwdyjgz (ynlkyltxgq ) View more	Positive	01 Mar 2020
NCT02665364 (Pubmed \| Arthritis Rheumatol) Manual	Phase 2	Systemic Lupus Erythematosus	185	Placebo	(xnafmfdnfd) = zhpmiztwap ccwjwdyjgz (ynlkyltxgq ) View more	Positive	01 Mar 2020